Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations.
Financial Results:
Caplin Point Laboratories Ltd reported Revenues for Q4FY23 of ₹389.00 Crores up from ₹339.00 Crore year on year, a rise of 14.75%.
Total Expenses for Q4FY23 of ₹276.00 Crores up from ₹250.00 Crores year on year, a rise of 10.4%.
Consolidated Net Profit of ₹101.00 Crores up 24.69% from ₹81.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹13.45, up 28.95% from ₹10.43 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.